Calcitonin gene-related peptide (CGRP) plays an important role as a vasodilator in local inflammation and response to injury. Various inflammatory mediators, including bradykinin (BK), histamine, and prostaglandins (PGs), trigger CGRP release from perivascular nerves, causing vasodilation. Elevated CGRP release is also thought to contribute to pathology of septic shock in human patients and endotoxemia (ETX) in animal models. ETX-induced CGRP release is partially blocked by cyclo-oxygenase inhibitors, suggestion role of PGs. Furthermore, other septic-shock mediators, such as BK and lactic acid, act synergistically to cause high levels of CGRP release [1] .
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In rat aortic rings, CGRP causes endothelium-dependent vasorelaxations and elevations of both cAMP and cGMP, all blocked by nitric oxide (NO) inhibitors [2] , indicating NO involvement. Exogenous NO synergistically enhances vasorelaxant and cAMP responses to CGRP in endothelium-denuded aortic rings [3] , suggesting endothelium-dependence of CGRPs responses involves NO potentiating direct (smooth muscle) effects of CGRP. These finding are especially relevant to septic shock, which involves elevated release of both CGRP and NO.
Recent studies from our laboratory show that both vasorelaxant responses in vitro and hypotensive responses in vivo to CGRP are severely impaired in elderly rats and young diabetic rats. These impairments may involve diminished NO release, known to occur in aging and diabetes, and damaging effects of glucose. Because endogenous CGRP is thought to serve as both antiatherogenic and antihypertensive agents, loss of these protective effects of CGRP during aging or diabetes may increase risks of developing atherosclerosis and hypertension.
